Dr. Priya Kapoor is a Consultant Clinical Geneticist and Principal Investigator at a Genomic Medicine Centre affiliated with the NHS England Genomics Programme, with 15 years of combined research and clinical experience. She completed her medical training at the University of Cambridge and holds a PhD in Cancer Genomics from the Institute of Cancer Research. She leads clinical trials in targeted therapy and advises patients on interpreting genetic test results.
Dr. Priya Kapoor completed her medical degree at the University of Cambridge before undertaking a PhD in Cancer Genomics at the Institute of Cancer Research in London, where her work contributed to the identification of novel drug targets in breast cancer subtypes. Over 15 years, she has built a dual career in clinical genetics and translational research, holding consultant posts at both the Royal Marsden Hospital and a regional NHS Genomic Medicine Centre. Priya is a certified Principal Investigator who has designed and led Phase II and Phase III clinical trials, giving her an intimate understanding of informed consent processes, ethics committee governance, and the real risks participants face. She is an authority on pharmacogenomics, explaining why two patients with identical diagnoses can respond entirely differently to the same medication based on their genetic profile. Her expertise extends to direct-to-consumer DNA testing, where she helps patients distinguish between clinically validated genetic information and commercially driven health predictions. Dr. Kapoor is deeply familiar with the 100,000 Genomes Project, NICE technology appraisals for cancer drugs, and the ethical dilemmas surrounding predictive genetic testing for conditions like Huntington's disease. She writes because she believes every patient deserves to understand the science behind their treatment plan, whether they are considering a clinical trial, interpreting a pathology report, or deciding whether a private DNA test is worth the investment. Her articles bridge the gap between cutting-edge laboratory science and the real-world decisions patients face in consulting rooms.